Trang chủ › U tủy xương đa phát › Texas › Houston
Thử nghiệm lâm sàng cho U tủy xương đa phát tại Houston, TX
39 nghiên cứu cho U tủy xương đa phát đang tìm kiếm người tham gia tại các cơ sở ở Houston và vùng lân cận (bán kính khoảng 30 dặm). Mở nghiên cứu để xem tiêu chí tham gia và cách liên hệ với đội ngũ nghiên cứu.
Văn bản nghiên cứu chính thức (Tiếng Anh)
Đang tuyển dụng cho một nghiên cứu? Đưa tin của bạn lên đầu trang này — $99 trong 30 ngày →
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Đang tuyểnGiai đoạn 3
- Houston Methodist Cancer Center Infusion, Houston
- Houston Methodist Hospital - Department of Pharmacy, Houston
- Houston Methodist Hospital Cancer Center, Houston
- và 3 nữa
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Đang tuyểnGiai đoạn 3
- MD Anderson Cancer Center, Houston
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Đang tuyểnGiai đoạn 1
- Oncology Consultants /ID# 268323, Houston
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Đang tuyểnGiai đoạn 4
- MD Anderson Cancer Center, Houston
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Đang tuyểnGiai đoạn 3
- Houston Methodist Hospital, Houston
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Đang tuyểnGiai đoạn 1
- MD Anderson Cancer Center, Houston
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Đang tuyểnGiai đoạn 3
- MD Anderson Cancer Center, Houston
Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia
Đang tuyểnNghiên cứu quan sát
- MDA, Houston
Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
Đang tuyểnGiai đoạn 2Chào đón tình nguyện viên khỏe mạnh
- MD Anderson Cancer Center, Houston
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
Đang tuyểnGiai đoạn 1
- Houston Methodist Hospital, Houston
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Đang tuyểnGiai đoạn 3
- University of Texas MD Anderson Cancer Center, Houston
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Đang tuyểnGiai đoạn 3
- The University of Texas MD Anderson Cancer Center, Houston
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Đang tuyểnGiai đoạn 1
- Oncology Consultants, Houston
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
Đang tuyểnGiai đoạn 3
- Research Site, Houston
Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients
Đang tuyểnGiai đoạn 2
- M D Anderson Cancer Center, Houston
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
Đang tuyểnGiai đoạn 1/2
- Research Site, Houston
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Đang tuyểnGiai đoạn 3
- The University of Texas MD Anderson Cancer Center, Houston
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Đang tuyểnGiai đoạn 1/2
- Research Site, Houston
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Đang tuyểnGiai đoạn 2
- University of Texas MD Anderson Cancer Center, Houston
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Đang tuyểnGiai đoạn 3
- Research Site, Houston
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
Đang tuyểnGiai đoạn 1
- Research Site, Houston
A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
Đang tuyểnGiai đoạn 1/2
- MD Anderson, Houston
A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
Đang tuyểnGiai đoạn 1
- Oncology Consultants (P1 Trials -Exigent Network), Houston
- Lumi Research, Houston
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Đang tuyểnGiai đoạn 2
- The University of Texas MD Anderson Cancer Center, Houston
A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"
Đang tuyểnGiai đoạn 2
- MD Anderson Cancer Center, Houston
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
Đang tuyểnGiai đoạn 1/2
- MD Anderson Cancer Center, Houston
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
Đang tuyểnGiai đoạn 1/2
- University of Texas MD Anderson Cancer Center, Houston
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
Đang tuyểnGiai đoạn 1/2
- MD Anderson Cancer Center, Houston
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Đang tuyểnGiai đoạn 3
- Research Site, Houston
Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma
Đang tuyểnGiai đoạn 1/2
- M D Anderson Cancer Center, Houston
Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma
Đang tuyểnGiai đoạn 2
- MD Anderson Cancer Center, Houston
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
Đang tuyểnGiai đoạn 1/2
- M D Anderson Cancer Center, Houston
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Đang tuyểnGiai đoạn 1
- University of Texas MD Anderson Cancer Center, Houston
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Đang tuyểnGiai đoạn 3
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
- M D Anderson Cancer Center, Houston
- và 2 nữa
Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
Đang tuyểnNghiên cứu quan sát
- M D Anderson Cancer Center, Houston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Đang tuyểnGiai đoạn 1
- MD Anderson Cancer Center, Houston
ATRA and Carfilzomib in Plasma Cell Myeloma Patients
Đang tuyểnGiai đoạn 1/2
- Houston Methodist Neal Cancer Center, Houston
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Đang tuyểnGiai đoạn 1/2
- MDACC, Houston
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Đang tuyểnGiai đoạn 1/2
- University of Texas MD Anderson Cancer Center, Houston
Thử nghiệm cho U tủy xương đa phát tại các thành phố khác
- New York City, NY59 nghiên cứu
- Boston, MA45 nghiên cứu
- Atlanta, GA42 nghiên cứu
- Durham, NC36 nghiên cứu
- Nashville, TN31 nghiên cứu
- Denver, CO26 nghiên cứu
- St. Louis, MO26 nghiên cứu
- Rochester, MN25 nghiên cứu
- Columbus, OH25 nghiên cứu
- Chicago, IL24 nghiên cứu
- Milwaukee, WI23 nghiên cứu
- Baldwin Park, CA23 nghiên cứu
Các nghiên cứu khác tại Houston
- Ung thư phổi không tế bào nhỏ143 nghiên cứu
- Ung thư vú126 nghiên cứu
- Ung thư (mọi loại)124 nghiên cứu
- Ung thư đại trực tràng101 nghiên cứu
- Ung thư di căn100 nghiên cứu
- Ung thư buồng trứng90 nghiên cứu
- Bạch cầu tủy cấp88 nghiên cứu
- Ung thư phổi78 nghiên cứu
- Ung thư tuyến tiền liệt73 nghiên cứu
- Ung thư nội mạc tử cung69 nghiên cứu
- Ung thư hắc tố61 nghiên cứu
- Ung thư tụy59 nghiên cứu
Nguồn dữ liệu từ ClinicalTrials.gov, cập nhật ngày 15 thg 11, 2026. Mỗi nghiên cứu có tiêu chí riêng; đội ngũ nghiên cứu sẽ quyết định ai đủ điều kiện tham gia.